The American Journal of Managed Care: Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics
First-line treatment for advanced urothelial carcinoma has evolved in recent years from traditional chemotherapy to targeted immunotherapy drugs enfortumab vedotin (Padcev) and pembrolizumab (Keytruda ...
Please provide your email address to receive an email when new articles are posted on . Zongertinib conferred benefits in PFS and response as a first-line treatment option for HER2-mutant advanced non ...
In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted ...
Please provide your email address to receive an email when new articles are posted on . First-line treatment with nivolumab-ipilimumab improved PFS and response compared with monotherapy for certain ...
Cure Today: NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC
Medscape: PT Safe and Effective First-Line Treatment for Chronic Low Back Pain
Findings of a real-world study confirm guidelines that recommend physical therapy as first-line treatment; it has a slight edge over cognitive-behavioral therapy.
The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...